- Home
- FFR vs CTSO Comparison
FFR vs CTSO Comparison
Compare FFR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFR | CTSO |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 23.9M |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FFR | CTSO |
|---|---|---|
| Price | $0.75 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 259.2K | 64.3K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.79 | ★ 65.79 |
| EPS | N/A | ★ N/A |
| Revenue | $4,983,556.00 | ★ $22,503,908.00 |
| Revenue This Year | N/A | $4.91 |
| Revenue Next Year | N/A | $13.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.76 | $0.30 |
| 52 Week High | $2.05 | $7.44 |
Technical Indicators
Market Signals| Indicator | FFR | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 51.51 |
| Support Level | N/A | $2.88 |
| Resistance Level | $2.05 | $7.20 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 4.93 | 48.00 |
Price Performance
Historical ComparisonAbout FFR FF EAI Robotics Ecosystem Inc. Common Stock
FF EAI Robotics Ecosystem Inc is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. The company focuses on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.
About CTSO Cytosorbents Corporation
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.